Prof. (Emeritus) Danny Michaelson
Research work
Alzheimer's disease (AD) cannot be treated effectively. Since AD is heterogeneous a possible approach to this problem is to focus on subpopulations of AD patients which share common genetic risk factors. Apolipoprotein E4 (apoE4), which is the most prevalent genetic risk factor for AD, presents such a therapeutic target.
The overall objective of our research is to study the mechanisms underlying the pathological effects of apoE4 and to develop anti- apoE targeted therapeutic strategies .The latter are based on immunotherapy as well as on repairing structural impairments of apoE4 such as impaired lipidation .The experiments are performed at both the in vitro and in vivo levels utilizing the appropriate cell cultures and transgenic mice .
Areas of interest & scientific knowledge
Brain Disorders Research
Cellular & Molecular Neuroscience
Cognitive Neuroscience
Methodology
Animal StudiesSelected Publications
- Shira Simonovitch , Eran Schmukler , Eliezer Masliah , Ronit Pinkas-Kramarski a, and Daniel M. Michaelson (2019). The effects of APOE4 on mitochondrial dynamics and proteins in vivo.
- Salomon-Zimri S, Koren A, Angel A, Ben-Zur T, Offen D, Michaelson DM.(2019). The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo.Curr Alzheimer Res. 2019;16(4):281-292. doi: 10.2174/1567205016666190228120254.
- Safieh M, Korczyn AD, Michaelson DM (2019) ApoE4: an emerging therapeutic target for Alzheimer's disease. BMC Med 17(1) :64 . doi: 10.1186/s12916-019-1299
- Schmukler E, Michaelson DM, Pinkas-Kramarski R. The Interplay Between Apolipoprotein E4 and the Autophagic-Endocytic-Lysosomal Axis (2018). Mol Neurobiol. s12035-018-0892-4
- Bar R, Boehm-Cagan A, Luz I, Kleper-Wall Y, Michaelson DM. (2017) .The effects of apolipoprotein E genotype, α-synuclein deficiency, and sex on brain synaptic and Alzheimer's disease-related pathology. Alzheimers Dement (Amst). 6;10:1-11.
